Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis

A method of treating or slowing the progression of liver disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of topiramate in combination with a therapeutically effective amount of phentermine, wherein the liver disease is non-alcoholic steatohepatitis (NASH) and wherein the therapeutically effective amount of topiramate is selected from 46 mg per day and 92 mg per day and the therapeutically effective amount of phentermine is selected from 7.5 mg per day and 15 mg per day wherein the 7.5 mg phentermine is provided as 9.33 mg phentermine hydrochloride and the 15 mg phentermine is provided as 18.66 mg phentermine hydrochloride.

A method of delaying the progression from NAFLD to NASH in a patient, comprising:

• identifying a patient having NAFLD and administering to the patient an oral dosage form comprising immediate release phentermine and controlled release topiramate.

A method of delaying the progression from NASH to liver cirrhosis in a patient, comprising:

• identifying a patient having NASH and administering to the patient an oral dosage form comprising:
• a) 3.75 mg immediate release phentermine in combination with 23 mg controlled release topiramate, or b) 7.5 mg immediate release phentermine in combination with 46 mg controlled release topiramate, or c) 11.25 mg immediate release phentermine in combination with 69 mg controlled release topiramate, or d) 15 mg immediate release phentermine in combination with 92 mg controlled release topiramate.